Alnylam schedules five-year HELIOS-B follow-up at AHA
Company / institutional announcement · Alnylam
Source published: · Event / reporting date: 2026-11-03
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What changed
Alnylam announced AHA and ISA presentations covering vutrisiran in transthyretin amyloidosis, including five-year HELIOS-B follow-up with two years of open-label extension data. Planned analyses also examine exercise capacity, cardiopulmonary measures, and real-world treatment patterns. The announcement previews forthcoming presentations; open-label and post hoc analyses require interpretation distinct from randomized comparisons.
Why it may matter
Analysis: Longer follow-up may inform durability and treatment pathways, but extension and indirect analyses cannot substitute for randomized comparative evidence.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections